Osaka, Japan – March 27, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) ... Read More
Maple Grove, MN – March 27, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluoxetine Tablets, USP, 10 and 20 mg. Upsher-Smith’s product is AB-rated to the branded product, Prozac® (fluoxetine) tablets, ... Read More
Osaka, Japan – March 6, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) ... Read More
Osaka, Japan – February 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for three compounds with six strengths ... Read More
Forty Awardees Chosen for Their Outstanding Role in Advancing Patient Care
Maple Grove, MN – February 6, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are pleased to recognize the ... Read More
Pharmaceutical Company Highlights Past Achievements, Future Endeavors
Maple Grove, MN – January 28, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith), a US- based pharmaceutical company that has successfully delivered medications to the people who need them for ... Read More
Osaka, Japan – January 9, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) ... Read More
Osaka, Japan – December 13, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of six compounds with 14 strengths of generic drugs. They will be ... Read More